Condition: Low Grade Upper Tract Urothelial Carcinoma · Sponsor: Tyra Biosciences, Inc
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
This description comes directly from the study's public registry record.
Grace Indyk · 858-356-2323 · TyraClinicalTrials@tyra.bio
Always discuss trial participation with your own doctor first.
| The Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | Recruiting |
| Duly Health and Care Chicago | Lisle, Illinois, United States | Recruiting |
| Urology of Indiana, LLC | Greenwood, Indiana, United States | Recruiting |
| First Urology | Jeffersonville, Indiana, United States | Recruiting |
| Greater Boston Urology - Plymouth Care Center | Plymouth, Massachusetts, United States | Recruiting |
| Urology of St. Louis | St Louis, Missouri, United States | Recruiting |
| Summit Health - Washington Township | Sewell, New Jersey, United States | Recruiting |
| Albany Medical College | Albany, New York, United States | Recruiting |
| Associated Medical Professionals of NY, PLLC | Syracuse, New York, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Central Ohio Urology Group | Gahanna, Ohio, United States | Recruiting |
| Urology Associates, P C | Nashville, Tennessee, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07265947